nps-568 has been researched along with Hyperparathyroidism, Secondary in 29 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 28 (96.55) | 29.6817 |
| 2010's | 1 (3.45) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ben-Dov, IZ; Naveh-Many, T; Nechama, M; Silver, J | 1 |
| Davis, J; Fotsch, C; Harrington, PE; Henley, C; Lott, FD; Lu, JY; Morony, S; Poon, SF; Reagan, JD; St Jean, DJ; Yang, Y | 1 |
| Davis, J; Fan, W; Florio, M; Fotsch, C; Henley, C; Lu, JY; Morony, S; Pretorius, JK; Reagan, JD; Richards, WG; Shatzen, E; St Jean, DJ; Sun, B; Yang, Y | 1 |
| Goodman, WG; Turner, SA | 1 |
| Drüeke, TB | 1 |
| Amann, K; Odoni, G; Ogata, H; Orth, SR; Ritz, E | 1 |
| Frazão, JM; Ureña, P | 1 |
| Negri, AL; Slatopolsky, EA | 1 |
| Goodman, WG | 3 |
| Franceschini, N; Joy, MS; Kshirsagar, AV | 1 |
| Krebs, LJ | 1 |
| Nagano, N; Nemeth, EF | 1 |
| Lindberg, JS | 1 |
| Nagano, N | 1 |
| Akizawa, T; Hatamura, I; Kinugasa, E; Mizobuchi, M; Negi, S; Ogata, H; Saji, F; Sato, T; Shibata, M; Shiizaki, K | 1 |
| Cunningham, J | 1 |
| Ben-Dov, IZ; Dinur, M; Lavi-Moshayoff, V; Levi, R; Martin, D; Naveh-Many, T; Silver, J | 1 |
| de Vernejoul, MC; Legoupil, N; Ureña, P | 1 |
| Craig, JC; Elder, G; Messa, P; Palmer, S; Strippoli, GF; Tong, A | 1 |
| Akizawa, T; Kinugasa, E; Koiwa, F; Ogata, H | 1 |
| Berger, I; Geldyyev, A; Gross, ML; Kokeny, G; Koleganova, N; Nakagawa, K; Piecha, G; Ritz, E; Schmitt, CP | 1 |
| Chin, J; Fox, J; Furuya, Y; Nagano, N; Nemeth, EF; Wada, M | 1 |
| Fox, J; Furuya, Y; Ishii, H; Nagano, N; Nemeth, EF; Wada, M | 1 |
| Chin, JI; Fox, J; Miller, SC; Nagano, N; Nemeth, EF; Wada, M | 1 |
| Coburn, JW; Frazao, JM; Goodkin, DA; Goodman, WG; Liu, W; Turner, SA | 1 |
| Brzac, HT; Pavlovic, D | 1 |
| Lewin, E; Olgaard, K | 1 |
17 review(s) available for nps-568 and Hyperparathyroidism, Secondary
| Article | Year |
|---|---|
Future role of calcimimetics in end-stage renal disease.
Topics: Aniline Compounds; Calcium; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Phenethylamines; Propylamines; Receptors, Calcium-Sensing; Receptors, Cell Surface | 2002 |
Treatment of secondary hyperparathyroidism with vitamin D derivatives and calcimimetics before and after start of dialysis.
Topics: Aniline Compounds; Calcium; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Phenethylamines; Propylamines; Vitamin D | 2002 |
Calcimimetic agents: review and perspectives.
Topics: Aniline Compounds; Animals; Calcium; Clinical Trials as Topic; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Parathyroid Hormone; Phenethylamines; Propylamines; Receptors, Calcium-Sensing | 2003 |
[Calcimimetic agents in the treatment of hyperparathyroidism secondary to chronic renal failure].
Topics: Aniline Compounds; Animals; Bone Diseases; Calcium; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Phenethylamines; Propylamines; Receptors, Calcium-Sensing; Receptors, Cell Surface | 2003 |
Calcimimetic agents and secondary hyperparathyroidism: rationale for use and results from clinical trials.
Topics: Aniline Compounds; Child; Cinacalcet; Clinical Trials as Topic; Humans; Hyperparathyroidism, Secondary; Naphthalenes; Parathyroid Hormone; Phenethylamines; Propylamines; Receptors, Calcium-Sensing | 2003 |
Calcimimetics and the treatment of primary and secondary hyperparathyroidism.
Topics: Aniline Compounds; Animals; Cinacalcet; Half-Life; Humans; Hyperparathyroidism, Secondary; Metabolic Clearance Rate; Naphthalenes; Phenethylamines; Propylamines; Randomized Controlled Trials as Topic; Rats | 2004 |
Calcimimetic agents for the treatment of secondary hyperparathyroidism.
Topics: Aniline Compounds; Cinacalcet; Clinical Trials as Topic; Humans; Hyperparathyroidism, Secondary; Naphthalenes; Phenethylamines; Propylamines | 2004 |
Calcimimetics and hyperparathyroidism.
Topics: Aniline Compounds; Calcium; Humans; Hyperparathyroidism; Hyperparathyroidism, Secondary; Parathyroid Hormone; Phenethylamines; Propylamines; Receptors, Calcium-Sensing | 2004 |
Functional proteins involved in regulation of intracellular Ca(2+) for drug development: the extracellular calcium receptor and an innovative medical approach to control secondary hyperparathyroidism by calcimimetics.
Topics: Aniline Compounds; Animals; Calcium; Cinacalcet; Clinical Trials as Topic; Drug Design; Drug Evaluation, Preclinical; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Models, Biological; Molecular Structure; Naphthalenes; Parathyroid Glands; Parathyroid Hormone; Phenethylamines; Propylamines; Rats; Receptors, Calcium-Sensing | 2005 |
Calcimimetics: a new tool for management of hyperparathyroidism and renal osteodystrophy in patients with chronic kidney disease.
Topics: Aniline Compounds; Calcium; Chronic Kidney Disease-Mineral and Bone Disorder; Cinacalcet; Humans; Hyperparathyroidism; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Naphthalenes; Phenethylamines; Propylamines; Vitamin D | 2005 |
Pharmacological and clinical properties of calcimimetics: calcium receptor activators that afford an innovative approach to controlling hyperparathyroidism.
Topics: Aniline Compounds; Animals; Calcium; Cinacalcet; Humans; Hyperparathyroidism, Primary; Hyperparathyroidism, Secondary; Naphthalenes; Parathyroid Hormone; Phenethylamines; Propylamines; Receptors, Calcium-Sensing | 2006 |
[Management of secondary hyperparathyroidism].
Topics: Aniline Compounds; Calcinosis; Calcium; Cinacalcet; Clinical Trials as Topic; Drug Design; Drug Therapy, Combination; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Naphthalenes; Parathyroid Hormone; Phenethylamines; Phosphorus; Polyamines; Practice Guidelines as Topic; Propylamines; Receptors, Calcium-Sensing; Sevelamer; Vascular Diseases; Vitamin D | 2005 |
[Calcimimetics, mechanisms of action and therapeutic applications].
Topics: Aniline Compounds; Animals; Bone Remodeling; Calcium; Cells, Cultured; Cinacalcet; Double-Blind Method; Female; Humans; Hyperparathyroidism; Hyperparathyroidism, Primary; Hyperparathyroidism, Secondary; Hyperplasia; Male; Middle Aged; Multicenter Studies as Topic; Naphthalenes; Parathyroid Glands; Parathyroid Hormone; Parathyroid Neoplasms; Phenethylamines; Propylamines; Randomized Controlled Trials as Topic; Rats; Receptors, Calcium-Sensing; Renal Dialysis; Risk Factors; Time Factors; Uremia | 2005 |
Meta-analysis of biochemical and patient-level effects of calcimimetic therapy.
Topics: Aniline Compounds; Calcium; Chronic Disease; Cinacalcet; Humans; Hyperparathyroidism, Secondary; Kidney Diseases; Naphthalenes; Phenethylamines; Propylamines; Randomized Controlled Trials as Topic | 2006 |
CKD-MBD: impact on management of kidney disease.
Topics: Aniline Compounds; Bone Diseases, Metabolic; Calcium Metabolism Disorders; Cardiovascular Diseases; Chelating Agents; Cinacalcet; Disease Progression; Humans; Hyperparathyroidism, Secondary; Hyperphosphatemia; Lanthanum; Naphthalenes; Phenethylamines; Polyamines; Propylamines; Renal Insufficiency, Chronic; Sevelamer; Vitamin D; Vitamin D Deficiency; Vitamins | 2007 |
Prevention of uremic bone disease using calcimimetic compounds.
Topics: Aniline Compounds; Calcium; Chronic Kidney Disease-Mineral and Bone Disorder; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Phenethylamines; Propylamines; Receptors, Calcium-Sensing; Receptors, Cell Surface; Treatment Outcome; Uremia | 2001 |
Calcimimetic agents and secondary hyperparathyroidism: treatment and prevention.
Topics: Aniline Compounds; Calcium; Clinical Trials as Topic; Humans; Hyperparathyroidism, Secondary; Hyperplasia; Parathyroid Glands; Phenethylamines; Propylamines | 2002 |
1 trial(s) available for nps-568 and Hyperparathyroidism, Secondary
| Article | Year |
|---|---|
A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism.
Topics: Adult; Aniline Compounds; Area Under Curve; Calcium; Double-Blind Method; Female; Humans; Hyperparathyroidism, Secondary; Hypocalcemia; Kidney Failure, Chronic; Male; Middle Aged; Parathyroid Hormone; Phenethylamines; Propylamines | 2000 |
11 other study(ies) available for nps-568 and Hyperparathyroidism, Secondary
| Article | Year |
|---|---|
Regulation of PTH mRNA stability by the calcimimetic R568 and the phosphorus binder lanthanum carbonate in CKD.
Topics: 3' Untranslated Regions; Adenine; Aniline Compounds; Animals; Calcium; Chronic Disease; Disease Models, Animal; Half-Life; Hyperparathyroidism, Secondary; Kidney Diseases; Lanthanum; Male; Parathyroid Glands; Parathyroid Hormone; Phenethylamines; Phosphates; Phosphorus, Dietary; Propylamines; Rats; RNA Stability; RNA-Binding Proteins; RNA, Messenger; Time Factors; Trans-Activators | 2009 |
Discovery and optimization of substituted 1-(1-phenyl-1H-pyrazol-3-yl)methanamines as potent and efficacious type II calcimimetics.
Topics: Administration, Oral; Aniline Compounds; Animals; Biological Availability; Cell Line; Crystallography, X-Ray; Humans; Hyperparathyroidism, Secondary; Male; Methylamines; Molecular Structure; Parathyroid Hormone; Phenethylamines; Propylamines; Pyrazoles; Rats; Rats, Sprague-Dawley; Receptors, Calcium-Sensing; Stereoisomerism; Structure-Activity Relationship | 2009 |
Discovery of a calcimimetic with differential effects on parathyroid hormone and calcitonin secretion.
Topics: Aniline Compounds; Animals; Biphenyl Compounds; Calcitonin; Calcium; CHO Cells; Cricetinae; Cricetulus; Diethylamines; HEK293 Cells; Humans; Hyperparathyroidism, Secondary; Hypocalcemia; Inositol Phosphates; Kidney Failure, Chronic; Male; Parathyroid Glands; Parathyroid Hormone; Phenethylamines; Phosphorylation; Propylamines; Rats; Rats, Sprague-Dawley; Receptors, Calcium-Sensing; Renal Dialysis | 2011 |
Beneficial effects of calcimimetics on progression of renal failure and cardiovascular risk factors.
Topics: Aniline Compounds; Animals; Blood Pressure; Calcium; Cardiovascular Diseases; Disease Progression; Hyperparathyroidism, Secondary; Kidney; Lipid Metabolism; Male; Models, Animal; Myocardium; Parathyroidectomy; Phenethylamines; Propylamines; Rats; Rats, Sprague-Dawley; Renal Insufficiency; Risk Factors; Ventricular Remodeling | 2003 |
[Apoptosis: a possible mechanism of suppressing parathyroid hyperplasia by calcimimetics].
Topics: Aniline Compounds; Animals; Apoptosis; Calcitriol; Cells, Cultured; Disease Models, Animal; Dose-Response Relationship, Drug; Hyperparathyroidism, Secondary; Male; Parathyroid Glands; Parathyroid Hormone; Phenethylamines; Propylamines; Rats; Rats, Sprague-Dawley; Receptors, Calcium-Sensing | 2005 |
Increased parathyroid hormone gene expression in secondary hyperparathyroidism of experimental uremia is reversed by calcimimetics: correlation with posttranslational modification of the trans acting factor AUF1.
Topics: Aniline Compounds; Animals; Gene Expression Regulation; Heterogeneous Nuclear Ribonucleoprotein D0; Heterogeneous-Nuclear Ribonucleoprotein D; Hyperparathyroidism, Secondary; Male; Parathyroid Hormone; Phenethylamines; Propylamines; Protein Processing, Post-Translational; Rats; RNA, Messenger; Uremia | 2006 |
Calcimimetic R-568 or calcitriol: equally beneficial on progression of renal damage in subtotally nephrectomized rats.
Topics: Albuminuria; Aniline Compounds; Animals; Calcitriol; Calcium; Disease Models, Animal; Glomerular Filtration Rate; Hyperparathyroidism, Secondary; Kidney; Kidney Tubules; Male; Nephrectomy; Phenethylamines; Propylamines; Rats; Rats, Sprague-Dawley; Receptors, Calcium-Sensing | 2008 |
Calcimimetic NPS R-568 prevents parathyroid hyperplasia in rats with severe secondary hyperparathyroidism.
Topics: Aniline Compounds; Animals; Blood Urea Nitrogen; Body Weight; Calcium; Hyperparathyroidism, Secondary; Hyperplasia; Male; Parathyroid Diseases; Parathyroid Hormone; Phenethylamines; Propylamines; Rats; Rats, Sprague-Dawley | 2000 |
Daily intermittent decreases in serum levels of parathyroid hormone have an anabolic-like action on the bones of uremic rats with low-turnover bone and osteomalacia.
Topics: Aniline Compounds; Animals; Bone and Bones; Bone Density; Calcium; Chronic Kidney Disease-Mineral and Bone Disorder; Disease Models, Animal; Doxorubicin; Humans; Hyperparathyroidism, Secondary; Male; Osteomalacia; Parathyroid Hormone; Phenethylamines; Phosphates; Propylamines; Rats; Rats, Sprague-Dawley; Uremia | 2000 |
Activation of the calcium receptor by a calcimimetic compound halts the progression of secondary hyperparathyroidism in uremic rats.
Topics: Analysis of Variance; Aniline Compounds; Animals; Blood Urea Nitrogen; Calcium; Calcium-Binding Proteins; Creatinine; Hyperparathyroidism, Secondary; Hyperplasia; Parathyroid Glands; Parathyroid Hormone; Phenethylamines; Phosphates; Propylamines; Rats; Rats, Sprague-Dawley; Steroid Hydroxylases; Uremia | 2000 |
Criteria for calcimimetic agent in the treatment of more severe secondary hyperparathyroidism.
Topics: Aniline Compounds; Humans; Hyperparathyroidism, Secondary; Phenethylamines; Propylamines; Severity of Illness Index | 2001 |